Search alternatives:
significant cases » significant cause (Expand Search), significant based (Expand Search), significant changes (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
cases based » case based (Expand Search), scores based (Expand Search), values based (Expand Search)
significant cases » significant cause (Expand Search), significant based (Expand Search), significant changes (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
cases based » case based (Expand Search), scores based (Expand Search), values based (Expand Search)
-
121
The base case analysis.
Published 2025“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”
-
122
Base-case results.
Published 2025“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”
-
123
-
124
-
125
-
126
-
127
Base-case results.
Published 2024“…The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. …”
-
128
Base-case analysis.
Published 2023“…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …”
-
129
<i>Kdm6a</i> conditional KO mice have decreased repopulating potential in serial competitive transplantation assays.
Published 2021“…(E) Quantification of donor cell chimerism of HSCs in BM by flow cytometry 18 weeks after secondary transplantation. Significant differences in the chimerism of SLAM cells compared to whole BM were found in KO-F mice (55.2-fold increase in CD45.2<sup>+</sup> KO-F SLAM cells as compared to CD45.2<sup>+</sup> cells in the whole BM, p = 0.0163) and KO-M mice (11.31-fold increase in CD45.2<sup>+</sup> KO-M SLAM cells as compared to CD45.2<sup>+</sup> cells in the whole BM, p = 0.0010). …”
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140